NCT04278833 is a Phase 4 clinical trial of Triamcinolone or Betamethasone in Osteoarthritis, sponsored by Stanford University.

Who is sponsoring NCT04278833?

NCT04278833 is sponsored by Stanford University.

What drugs are being tested in NCT04278833?

Interventions in NCT04278833: Triamcinolone or Betamethasone, Dexamethasone.

What condition does NCT04278833 study?

NCT04278833 studies Osteoarthritis, Tendinopathy, Impingement Shoulder.

Is NCT04278833 still recruiting?

NCT04278833 is currently terminated. Last updated 12 February 2025.

Are results published for NCT04278833?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-12 · How we verify

NCT04278833

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Effectiveness of Particulate Versus Nonparticulate Steroid Injections for Musculoskeletal Conditions

Terminated Phase 4 Results posted Last updated 12 February 2025

What this trial tests

Phase 4 trial testing Triamcinolone or Betamethasone in Osteoarthritis in 165 participants. Terminated before completion.

Timeline

1 September 2020

Primary endpoint
28 May 2021

28 May 2021

Quick facts

Lead sponsor	Stanford University
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	165
Start date	1 September 2020
Primary completion	28 May 2021
Estimated completion	28 May 2021
Sites	1 location across United States

Drugs / interventions tested

Triamcinolone or Betamethasone — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Osteoarthritis — all drugs for Osteoarthritis →
Tendinopathy — all drugs for Tendinopathy →
Impingement Shoulder — all drugs for Impingement Shoulder →

Sponsor

Stanford University

Who can join

18 and older, any sex, with Osteoarthritis or Tendinopathy. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Mean Change in Average Pain From Baseline Primary · Baseline and at 2 weeks, 3 months, and 6 months post intervention

Mean change in pain averaged over last 7 days compared to baseline as rated on 11 point numerical rating scale (NRS, score range from 0-10) with higher values indicating worse outcomes.

Baseline

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	6.0	± 2.1
Particulate Corticosteroid Injection - Hip Injection Site	5.1	± 3.1
Non-particulate Corticosteroid Injection - Shoulder Injection Site	5.9	± 2.2
Non-particulate Corticosteroid Injection - Hip Injection Site	5.0	± 3.3

2 weeks

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	-2.9	± 2.0
Particulate Corticosteroid Injection - Hip Injection Site	-2.0	± 2.5
Non-particulate Corticosteroid Injection - Shoulder Injection Site	-1.5	± 2.0
Non-particulate Corticosteroid Injection - Hip Injection Site	-1.8	± 2.3

3 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	-1.8	± 2.6
Particulate Corticosteroid Injection - Hip Injection Site	-1.8	± 3.3
Non-particulate Corticosteroid Injection - Shoulder Injection Site	-2.2	± 2.3
Non-particulate Corticosteroid Injection - Hip Injection Site	0.5	± 0.7

6 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	-1.6	± 2.7
Particulate Corticosteroid Injection - Hip Injection Site	-0.9	± 3.1
Non-particulate Corticosteroid Injection - Shoulder Injection Site	-2.1	± 2.7
Non-particulate Corticosteroid Injection - Hip Injection Site	-0.5	± 0.7

Number of Participants With ≥50% Decrease in Pain From Baseline Primary · Baseline and at 2 weeks, 3 months, and 6 months post intervention

Decrease in pain compared to baseline as rated on 11 point numerical rating scale (NRS, score range from 0-10) with higher values indicating worse outcomes.

2 weeks

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	4
Particulate Corticosteroid Injection - Hip Injection Site	3
Non-particulate Corticosteroid Injection - Shoulder Injection Site	13
Non-particulate Corticosteroid Injection - Hip Injection Site	3

3 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	6
Particulate Corticosteroid Injection - Hip Injection Site	3
Non-particulate Corticosteroid Injection - Shoulder Injection Site	18
Non-particulate Corticosteroid Injection - Hip Injection Site	0

6 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	8
Particulate Corticosteroid Injection - Hip Injection Site	2
Non-particulate Corticosteroid Injection - Shoulder Injection Site	13
Non-particulate Corticosteroid Injection - Hip Injection Site	0

Change in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index Secondary · Baseline and at 2 weeks, 3 months, and 6 months post intervention

The WOMAC questionnaire will be used for participants who underwent hip injection. The outcome of interest is the mean change in score compared to baseline. The WOMAC is a 24 item scale with scores ranging from 0 to 96, with higher scores indicating worse outcomes.

Baseline

Group	Value	95% CI
Particulate Corticosteroid Injection - Hip Injection Site	64.3	± 24.8
Non-particulate Corticosteroid Injection - Hip Injection Site	62.3	± 15.5

Change at 2 weeks

Group	Value	95% CI
Particulate Corticosteroid Injection - Hip Injection Site	-18.6	± 15.3
Non-particulate Corticosteroid Injection - Hip Injection Site	-10.3	± 12.1

Change at 3 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Hip Injection Site	-14.4	± 16.8
Non-particulate Corticosteroid Injection - Hip Injection Site	-4.0	± 10.1

Change at 6 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Hip Injection Site	-14.1	± 15.1
Non-particulate Corticosteroid Injection - Hip Injection Site	-1.0	± 11.0

Change in Quick Disabilities of Arm, Shoulder, and Hand (QDASH) Secondary · Baseline and at 2 weeks, 3 months, and 6 months post intervention

The QDASH questionnaire will be used for participants who underwent glenohumeral joint, subdeltoid bursa, or peritendinous biceps injection. The outcome of interest is the mean change in score compared to baseline. The QDASH is an 11 item scale with scores ranging from 0 to 100, with higher scores indicating worse outcomes.

Baseline

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	41.9	± 22.8
Non-particulate Corticosteroid Injection - Shoulder Injection Site	49.0	± 21.8

Change at 2 weeks

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	-15.7	± 12.2
Non-particulate Corticosteroid Injection - Shoulder Injection Site	-11.4	± 13.2

Change at 3 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	-9.1	± 12.3
Non-particulate Corticosteroid Injection - Shoulder Injection Site	-17.1	± 16.6

Change at 6 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	-15.5	± 16.4
Non-particulate Corticosteroid Injection - Shoulder Injection Site	-21.0	± 21.5

Change in American Shoulder and Elbow Surgeons (ASES) Standardized Shoulder Assessment Form Secondary · Baseline and at 2 weeks, 3 months, and 6 months post intervention

The ASES questionnaire will be used for participants who underwent glenohumeral joint, subdeltoid bursa, or peritendinous biceps injection. The outcome of interest is the mean change in score compared to baseline. The ASES is an 11 item scale with scores ranging from 0 to 100, with higher scores indicating better outcomes.

Baseline

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	62.9	± 19.7
Non-particulate Corticosteroid Injection - Shoulder Injection Site	61.5	± 19.2

Change at 2 weeks

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	18.0	± 12.7
Non-particulate Corticosteroid Injection - Shoulder Injection Site	12.8	± 14.5

Change at 3 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	14.1	± 18.1
Non-particulate Corticosteroid Injection - Shoulder Injection Site	20.3	± 20.8

Change at 6 months

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	18.1	± 22.1
Non-particulate Corticosteroid Injection - Shoulder Injection Site	23.9	± 26.2

Number of Participants With Repeat Corticosteroid Injections Secondary · 6 months post initial intervention

Total number of corticosteroid injections to the specific anatomical site during the study period. The study protocol allows for a maximum of 3 injections during the 6 month study period based on the treating physician's discretion.

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	6
Particulate Corticosteroid Injection - Hip Injection Site	2
Non-particulate Corticosteroid Injection - Shoulder Injection Site	2
Non-particulate Corticosteroid Injection - Hip Injection Site	1

Number of Participants Referred for Surgical Intervention (Conversion to Surgery) Secondary · 6 months post initial intervention

Number (%) of participants who were referred for surgical intervention on the specific anatomical site during the study follow up period.

Group	Value	95% CI
Particulate Corticosteroid Injection - Shoulder Injection Site	6
Particulate Corticosteroid Injection - Hip Injection Site	2
Non-particulate Corticosteroid Injection - Shoulder Injection Site	1
Non-particulate Corticosteroid Injection - Hip Injection Site	2

Sponsor's own description

This aims of this study are: 1. To determine if particulate or non-particulate corticosteroid injections are more effective at treating pain from musculoskeletal pathologies of the hip, glenohumeral joint, biceps tendon, or subacromial/subdeltoid bursa at 2 weeks, 3 months, or 6 months. 2. To determine if there is a significantly different side effect profile between particulate and non-particulate corticosteroids when used for hip, glenohumeral joint, biceps tendon, or subacromial/subdeltoid bursa injections.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Osteoarthritis

Currently open trials in the same condition.

NCT07404891 — Clinical Trial on the Efficacy and Safety of ALT001 in Osteoarthritis · NA · recruiting
NCT07118501 — A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System · recruiting
NCT06631638 — EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN)) · NA · recruiting
NCT07198750 — "Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis" · NA · recruiting
NCT07006714 — Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA) · Phase 4 · active not recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04278833 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 12 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04278833.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT04278833

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Osteoarthritis

Other Stanford University trials

Verify against primary sources